Chemo-immunotherapy of breast cancer using vesiculated α-tocopheryl succinate in combination with dendritic cell vaccination

Nutrition and Cancer

Volumn 53, Issue 2, 2005, Pages 177-193

  Ramanathapuram, Lalitha V ^a   Hahn, Tobias ^a   Dial, Sharon M ^a   Akporiaye, Emmanuel T ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL SUCCINATE; DENDRITIC CELL VACCINE; FLUORESCEIN ISOTHIOCYANATE; GAMMA INTERFERON; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; INTERLEUKIN 12P70; INTERLEUKIN 4; LIPOCORTIN 5; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL MATURATION; CELL VIABILITY; CLONOGENESIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; METASTASIS INHIBITION; MOUSE; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; SPLEEN LYMPHOCYTE; STATISTICAL ANALYSIS; SURVIVAL TIME; TH1 CELL; TH2 CELL; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CANCER VACCINES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COMBINED MODALITY THERAPY; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; HEAT-SHOCK PROTEINS; IMMUNOTHERAPY; IN SITU NICK-END LABELING; MICE; MICE, INBRED BALB C; VITAMIN E;

ANIMALIA; MURINAE; TOSCANA VIRUS;

EID: 33645931667     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1207/s15327914nc5302_7     Document Type: Article

References (49)

1. Neuzil J, Weber T, Gellert N, and Weber C: Selective cancer cell killing by alpha-tocopheryl succinate. Br J Cancer 84, 87-89, 2001.
2. Prasad KN, Kumar B, Yan XD, Hanson AJ, and Cole WC: Alpha-tocopheryl succinate, the most effective form of vitamin E for adjuvant cancer treatment: a review. J Am Coll Nutr 22, 108-117, 2003.
3. Webr T, Lu M, Andera L, Lahm H, Gellert N, et al.: Vitamin E succinate is a potent novel antineoplastic agent with high selectivity and cooperativity with tumor necrosis factor-related apoptosis-inducing ligand (Apo2 ligand) in vivo. Clin Cancer Res 8, 863-869, 2002.
4. Yu W, Sanders BG, and Kline K: RRR-alpha-tocopheryl succinate inhibits EL4 thymic lymphoma cell growth by inducing apoptosis and DNA synthesis arrest. Nutr Cancer 27, 92-101, 1997.
5. Yu W, Simmons-Menchaca M, Gapor A, Sanders BG, and Kline K: Induction of apoptosis in human breast cancer cells by tocopherols and tocotrienols. Nutr Cancer 33, 26-32, 1999.
6. Israel K, Yu W, Sanders BG, and Kline K: Vitamin E succinate induces apoptosis in human prostate cancer cells: role for Fas in vitamin E succinate-triggered apoptosis. Nutr Cancer 36, 90-100, 2000.
7. Dalen H and Neuzil J: Alpha-tocopheryl succinate sensitises a T lymphoma cell line to TRAIL-induced apoptosis by suppressing NF-kappaB activation. Br J Cancer 88, 153-158, 2003.
8. Malafa MP, Fokum FD, Mowlavi A, Abusief M, and King M: Vitamin E inhibits melanoma growth in mice. Surgery 131, 85-91, 2002.
9. Malafa MP and Neitzel LT: Vitamin E succinate promotes breast cancer tumor dormancy. J Surg Res 93, 163-170, 2000.
10. Ramanathapuram LV, Kobie II, Bearss D, Payne CM, Trevor KT, et al.: Alpha-tocopheryl succinate sensitizes established tumors to vaccination with nonmatured dendritic cells. Cancer Immunol Immunother 53, 580-588, 2004.
11. Barnett KT, Fokum FD, and Malafa MP: Vitamin E succinate inhibits colon cancer liver metastases. J Surg Res 106, 292-298, 2002.
12. Kogure K, Manabe S, Hama S, Tokumura A, and Fukuzawa K: Potentiation of anti-cancer effect by intravenous administration of vesiculated alpha-tocopheryl hemisuccinate on mouse melanoma in vivo. Cancer Lett 192, 19-24, 2003.
13. Ramanathapuram LV, Hahn T, Graner MW, Katsanis E, and Akporiaye ET: Vesiculated alpha-tocopheryl succinate enhances the anti-tumor effect of dendritic cell vaccines. Cancer Immunol Immunother 55, 166-177, 2006.
14. Steinman RM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9, 271-296, 1991.
15. Mule IJ: Dendritic cells: at the clinical crossroads. J Clin Invest 105, 707-708, 2000.
16. Chang AE, Redman BG, Whitfield JR, Nickoloff BJ, Braun TM, et al.: A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 8, 1021-1032, 2002.
17. Burdin N and Moingeon P: Cancer vaccines based on dendritic cells loaded with tumor-associated antigens. Cell Biol Toxicol 17, 67-75, 2001.
18. Fields RC, Shimizu K, and Mule JJ: Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 95, 9482-9487, 1998.
19. Gatza E and Okada CY: Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma. J Immunol 169, 5227-5235, 2002.
20. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, et al.: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4, 328-332, 1998.
21. Porgador A and Gilboa E: Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 182, 255-260, 1995.
22. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, et al.: Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell I-associated cytokines. J Exp Med 183, 87-97, 1996.
23. Coveney E, Wheatley GH III, and Lyerly HK: Active immunization using dendritic cells mixed with tumor cells inhibits the growth of primary breast cancer. Surgery 122, 228-234, 1997.
24. Gabrilovich DI, Ciernik IF, and Carbone DP: Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol 170, 101-110, 1996.
25. Gabrilovich DI, Nadaf S, Corak J, Berzofsky JA, and Carbone DP: Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Cell Immunol 170, 111-119, 1996.
26. Kobie JJ, Wu RS, Kurt RA, Lou S, Adelman MK, et al.: Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res 63, 1860-1864, 2003.
27. Lawson KA, Anderson K, Simmons-Menchaca M, Atkinson J, Sun L, et al.: Comparison of vitamin E derivatives alpha-TEA and VES in reduction of mouse mammary tumor burden and metastasis. Exp Biol Med 229, 954-963, 2004.
28. Basu S, Binder RJ, Ramalingam T, and Srivastava PK: CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 14, 303-313, 2001.
29. Wu RS, Kobie JJ, Besselsen DG, Fong TC, Mack VD, et al.: Comparative analysis of IFN-gamma B7.1 and antisense TGF-beta gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma. Cancer Immunol Immunother 50, 229-240, 2001.
30. McEarchern JA, Kobie JJ, Mack V, Wu RS, Meade-Tollin L, et al.: Invasion and metastasis of a mammary tumor involves TGF-beta signaling. Int J Cancer 91, 76-82, 2001.
31. Basu S, Binder RJ, Suto R, Anderson KM, and Srivastava PK: Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol 12, 1539-1546, 2000.
32. Feng H, Zeng Y, Graner MW, and Katsanis E: Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells. Blood 100, 4108-4115, 2002.
33. Somersan S, Larsson M, Fonteneau JF, Basu S, Srivastava P, et al.: Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells. J Immunol 167, 4844-4852, 2001.
34. Buttiglieri S, Galetto A, Forno S, De Andrea M, and Matera L: Influence of drug-induced apoptotic death on processing and presentation of tumor antigens by dendritic cells. Int J Cancer 106, 516-520, 2003.
35. Basu S and Srivastava PK: Fever-like temperature induces maturation of dendritic cells through induction of hsp90. Int Immunol 15, 1053-1061, 2003.
36. Bethke K, Staib F, Distler M, Schmitt U, Jonuleit H, et al.: Different efficiency of heat shock proteins (HSP) to activate human monocytes and dendritic cells: superiority of HSP60. J Immunol 169, 6141-6148, 2002.
37. Chen W, Syldath U, Bellmann K, Burkart V, and Kolb H: Human 60-kDa heat-shock protein: a danger signal to the innate immune system. J Immunol 162, 3212-3219, 1999.
38. Flohe SB, Bruggemann J, Lendemans S, Nikulina M, Meierhoff G, et al.: Human heat shock protein 60 induces maturation of dendritic cells versus a Th1-promoting phenotype. J Immunol 170, 2340-2348, 2003.
39. Zheng H, Dai J, Stoilova D, and Li Z: Cell surface targeting of heat shock protein gp96 induces dendritic cell maturation and antitumor immunity. J Immunol 167, 6731-6735, 2001.
40. Aslakson CJ and Miller FR: Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52, 1399-1405, 1992.
41. Anderson K, Simmons-Menchaca M, Lawson KA, Atkinson J, Sanders BG, et al.: Differential response of human ovarian cancer cells to induction of apoptosis by vitamin E succinate and vitamin E analogue, alpha-TEA. Cancer Res 64, 4263-4269, 2004.
42. Jizomoto H, Kanaoka E, and Hirano K: pH-sensitive liposomes composed of tocopherol hemisuccinate and of phosphatidylethanolamine including tocopherol hemisuccinate. Biochim Biophys Acta 1213, 343-348, 1994.
43. Neuzil J, Weber T, Schroder A, Lu M, Ostermann G, et al.: Induction of cancer cell apoptosis by alpha-tocopheryl succinate: molecular pathways and structural requirements. FASEB J 15, 403-415, 2001.
44. Todryk S, Melcher AA, Hardwick N, Linardakis E, Bateman A, et al.: Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J Immunol 163, 1398-1408, 1999.
45. Asea A, Kraeft SK, Kurt-Jones EA, Stevenson MA, Chen LB, et al.: HSP70 stimulates cytokine production through a CD14-dependent pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 6, 435-442, 2000.
46. Jin Y, Fuller L, Ciancio G, Burke GW III, Tzakis AG, et al.: Antigen presentation and immune regulatory capacity of immature and mature-enriched antigen presenting (dendritic) cells derived from human bone marrow. Hum Immunol 65, 93-103, 2004.
47. Mosser DD and Morimoto RI: Molecular chaperones and the stress of oncogenesis. Oncogene 23, 2907-2918, 2004.
48. Srivastava P: Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 20, 395-425, 2002.
49. Banchereau J and Steinman RM: Dendritic cells and the control of immunity. Nature 392, 245-252, 1998.